N-[(1-甲基-3-吡咯烷)甲基]-1-乙胺 | 959239-24-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-[(1-甲基-3-吡咯烷)甲基]-1-乙胺
• 英文名称: N-[(1-Methylpyrrolidin-3-YL)methyl]ethanamine
• CAS: 959239-24-8
• 化学式: C₈H₁₈N₂
• 分子量: 142.24
• InChiKey: IIZVKRZQUGSTEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090

文献信息

• FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF
  申请人：Tabomedex Biosciences, LLC

  公开号：US20170190713A1

  公开（公告）日：2017-07-06

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

  本文提供了作为MK2抑制剂有用的替代融合四环化合物。本发明还提供了所述化合物的药物组合物。本发明还提供了替代融合四环化合物的医药用途。
• BETA-LACTAMASE INHIBITORS
  申请人：SUTTON Larry

  公开号：US20100261700A1

  公开（公告）日：2010-10-14

  Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.

  广谱β-内酰胺酶抑制剂。某些抑制剂除了抑制β-内酰胺酶外，还表现出强效的抗生素活性。本发明的化合物设计成在β-内酰胺环裂解时生成可以灭活β-内酰胺酶的反应性基团。还提供了制备β-内酰胺酶抑制剂和表现出这种抑制作用的β-内酰胺类抗生素的方法。此外还提供了用于治疗或预防细菌感染的药物组合物和治疗此类感染的方法。
• DIAZACARBAZOLES AND METHODS OF USE
  申请人：Chen Huifen

  公开号：US20110118230A1

  公开（公告）日：2011-05-19

  The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及式（I），（I-a）和（I-b）的1,7-二氮杂咔唑化合物，其作为激酶抑制剂有用，更具体地作为检查点激酶1（chk1）抑制剂有用，因此可用作癌症治疗剂。本发明还涉及包含这些化合物的组合物，更具体地是药物组合物，并使用它们治疗各种形式的癌症和增生性疾病的方法，以及使用这些化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗的方法，或相关的病理条件。
• Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest
  申请人：Peng Jin

  公开号：US20090306035A1

  公开（公告）日：2009-12-10

  Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic formulations comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided.
• US7582627B2
  申请人：——

  公开号：US7582627B2

  公开（公告）日：2009-09-01